Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema
This first-in-human study builds upon basic research by providing safety and preliminary efficacy of sozinibercept (anti-VEGF-C/-D) in combination with aflibercept for DME.
Authors
- Ian M. Leitch (ORCID: https://orcid.org/0000-0002-2465-3036)
- Pravin U. Dugel
- David S. Boyer (ORCID: https://orcid.org/0000-0001-9219-1614)
- Nathan Steinle (ORCID: https://orcid.org/0000-0002-9323-6594)
- Joel Pearlman (ORCID: https://orcid.org/0000-0002-2295-7538)
- Cameron Stone
- Sunil Gupta (ORCID: https://orcid.org/0000-0001-8714-0281)
- Courtney Crawford (ORCID: https://orcid.org/0000-0003-2492-8172)
- Megan E. Baldwin
Institutions
- California Retina Consultants (US)
- Retinal Consultants of Arizona (US)
- Retina Specialty Institute (US)
- Asheville Cardiology Associates (US)
- Retina Vitreous Associates Medical Group (US)
Publication Details
- Journal
- Translational Vision Science & Technology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1167/tvst.13.12.32
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Amgen
- Regeneron Pharmaceuticals
- Apellis Pharmaceuticals
- Genentech
- Allergan
- Spark Therapeutics